Using BTK Inhibitors to Prevent Anaphylactic Drug Reactions
使用 BTK 抑制剂预防过敏性药物反应
基本信息
- 批准号:10329987
- 负责人:
- 金额:$ 19.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-02-22 至 2025-01-31
- 项目状态:未结题
- 来源:
- 关键词:Agammaglobulinaemia tyrosine kinaseAllergen ImmunotherapyAllergensAllergicAllergic ReactionAnaphylaxisAwardB-Cell Antigen ReceptorB-LymphocytesBasophilsBiological MarkersBiometryCCL2 geneCD34 geneCellsCellular biologyClinicalClinical ImmunologyClinical TrialsCutaneousDataDevelopmentDoctor of PhilosophyDoseEpinephrineExposure toFDA approvedFoodFrequenciesFundingGoalsGrantHistamineHumanHypersensitivityHypersensitivity skin testingIL8 geneIgEImmune responseImmunologistImmunologyImmunotherapyIn VitroInflammatoryInpatientsInsect StingInterleukin-6KineticsLearningLeukocytesLeukotriene C4LifeLogicMeasurementMediatingMediator of activation proteinMedicineMentorsMusNutsOralPathway interactionsPatient CarePatientsPenicillin AllergyPenicillinsPeripheralPharmaceutical PreparationsPharmacologyPhasePhenotypePhosphotransferasesPlasmaPreventive therapyPrincipal InvestigatorProductionProstaglandin D2ReactionReceptor SignalingResearchResearch DesignResearch PersonnelRiskRoleSamplingScientistSerumSeveritiesSignal PathwaySignal TransductionSkinSmall Interfering RNASpecificityStimulusStudy SkillsTNF geneTestingTissuesTrainingTranslational ResearchTreesTryptaseTyrosine Kinase InhibitorUniversitiesVenomsWorkX-Linked Agammaglobulinemiabeta-n-acetylhexosaminidasecare outcomescareercell typeclinical carecostcost effectivecytokinedesensitizationdesignexperimental studyfood challengehuman modelhuman tissuehumanized mouseimprovedin vivoin vivo Modelinhibitormast cellmedical schoolsmouse modelnovelnovel strategiesnovel therapeuticsopen labelpatient orientedpreventprofessorskillsskin prick teststandard of carestem cellstranslational physician
项目摘要
PROJECT SUMMARY/ABSTRACT
This proposal describes a 5-year training award to develop the academic career of the principal
investigator, Melanie C. Dispenza, MD, PhD, a board-certified allergist-immunologist at the Northwestern
University Feinberg School of Medicine. Her qualifications and background, combined with her current research
in preventing IgE-mediated activation of mast cells and basophils, make her uniquely qualified to study novel
therapies to prevent anaphylaxis. During the period of this proposal, Dr. Dispenza will continue to devote at least
75% effort towards patient-oriented translational research.
Anaphylaxis is a potentially life-threatening IgE-mediated systemic allergic reaction with no known
preventative therapies. There is a huge unmet need for therapies that can reduce the frequency and/or severity
of anaphylactic reactions from both accidental and intentional exposures, the latter including desensitizations
and immunotherapy. Bruton’s tyrosine kinase (BTK) is a key component of FcεRI signaling in human mast cells
and basophils. Pharmacologic inhibitors of BTK are generally well tolerated, and preliminary data show that BTK
inhibitors effectively block IgE-mediated human mast cell and basophil activation in vitro and in mouse models
of anaphylaxis in vivo. Thus, it may be possible to utilize BTK inhibitors to proactively prevent allergic reactions
including anaphylaxis. The overarching hypothesis of this proposal is that short-term use of FDA-approved BTK
inhibitors such as ibrutinib will prevent medication-induced anaphylaxis in both mouse models of anaphylaxis
and in humans. If successful, BTK inhibitors could potentially be used to make drug desensitization safer and
more cost effective, thus improving patient care and outcomes.
Through this proposed research, Dr. Dispenza will work towards her long-term goal of becoming an
independent translational physician-scientist. Short-term goals include (1) expanding research skills in mast cell
biology, (2) learning to implement novel humanized mouse models of anaphylaxis, and (3) acquiring biostatistical
and clinical trial skills for study design and implementation. After completion of this award, Dr. Dispenza will
have had the needed training to design and implement further studies on the development of novel strategies to
prevent anaphylaxis. To achieve these goals, an excellent mentoring team has been assembled. The primary
mentor, Bruce Bochner, MD (Professor, Division of Allergy-Immunology, Department of Medicine), has a strong
track record of translational research in allergy including mast cell biology and has successfully trained many
academicians. Donald MacGlashan, Jr, MD, PhD (Director, Division of Allergy and Clinical Immunology, Johns
Hopkins University), will serve as co-mentor, with additional expertise in mast cell and basophil activation and
signaling. The mentoring team will oversee Dr. Dispenza’s progress in developing the necessary skills in order
to support her transition into an independent investigator.
项目摘要/摘要
这项建议描述了一项为期5年的培训奖励,以发展校长的学术生涯。
研究员,Melanie C.Dispenza,医学博士,西北大学董事会认证的过敏症专科医生和免疫学家
费恩伯格大学医学院。她的资历和背景,结合她目前的研究
在防止IgE介导的肥大细胞和嗜碱性粒细胞激活方面,使她成为唯一有资格研究小说的人
预防过敏反应的疗法。在这项提议期间,Dispenza博士将继续致力于至少
75%的精力用于以患者为导向的翻译研究。
过敏反应是一种潜在威胁生命的IgE介导的全身性过敏反应,目前尚不清楚
预防性治疗。有一个巨大的未得到满足的治疗需求,可以降低频率和/或严重程度
意外暴露和故意暴露引起的过敏反应,后者包括脱敏
和免疫疗法。布鲁顿酪氨酸激酶是人肥大细胞FcεRI信号的关键成分
以及嗜碱性粒细胞。BTK的药物抑制剂一般耐受性良好,初步数据显示BTK
在体外和小鼠模型中,抑制剂有效地阻断IgE介导的人肥大细胞和嗜碱性粒细胞的激活
体内的过敏性反应。因此,利用btk抑制剂主动预防过敏反应是可能的。
包括过敏反应。这项提议的首要假设是,短期使用FDA批准的BTK
伊布鲁替尼等抑制剂可以预防两种过敏反应模型的药物引起的过敏反应。
在人类身上也是如此。如果成功,BTK抑制剂可能被用于使药物脱敏更安全和
更具成本效益,从而改善患者护理和结果。
通过这项拟议的研究,Dispenza博士将努力实现她的长期目标,即成为
独立翻译医生兼科学家。短期目标包括(1)扩大肥大细胞的研究技能
生物学,(2)学习实现过敏反应的新的人性化小鼠模型,以及(3)获得生物统计学
以及研究设计和实施的临床试验技能。在完成这一奖项后,Dispenza博士将
接受了所需的培训,以设计和实施关于制定新战略的进一步研究
预防过敏反应。为了实现这些目标,已经组建了一支优秀的指导团队。初级阶段
导师布鲁斯·博什内尔医学博士(医学系过敏免疫科教授)
有包括肥大细胞生物学在内的过敏症翻译研究的记录,并成功地培训了许多
院士们。Donald Macglashan,Jr,MD,PhD(Johns过敏和临床免疫学部主任
将担任共同导师,并拥有肥大细胞和嗜碱性粒细胞激活方面的额外专业知识
发信号。指导团队将监督Dispenza博士在培养必要技能方面的进展
以支持她转变为独立调查员。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Melanie C. Dispenza其他文献
Research Advances in Mast Cell Biology and Their Translation Into Novel Therapies for Anaphylaxis
肥大细胞生物学研究进展及其在过敏反应新疗法中的转化
- DOI:
10.1016/j.jaip.2023.03.015 - 发表时间:
2023-07-01 - 期刊:
- 影响因子:6.600
- 作者:
Melanie C. Dispenza;Dean D. Metcalfe;Ana Olivera - 通讯作者:
Ana Olivera
Melanie C. Dispenza的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Melanie C. Dispenza', 18)}}的其他基金
Using BTK Inhibitors to Prevent Anaphylactic Drug Reactions
使用 BTK 抑制剂预防过敏性药物反应
- 批准号:
10112819 - 财政年份:2020
- 资助金额:
$ 19.56万 - 项目类别:
Using BTK Inhibitors to Prevent Anaphylactic Drug Reactions
使用 BTK 抑制剂预防过敏性药物反应
- 批准号:
10844835 - 财政年份:2020
- 资助金额:
$ 19.56万 - 项目类别:
Using BTK Inhibitors to Prevent Anaphylactic Drug Reactions
使用 BTK 抑制剂预防过敏性药物反应
- 批准号:
9890681 - 财政年份:2020
- 资助金额:
$ 19.56万 - 项目类别:
Using BTK Inhibitors to Prevent Anaphylactic Drug Reactions
使用 BTK 抑制剂预防过敏性药物反应
- 批准号:
10551351 - 财政年份:2020
- 资助金额:
$ 19.56万 - 项目类别:
相似海外基金
Immunological profiling of multi-food allergen immunotherapy assessing humoral and cellular activation profiles
多种食物过敏原免疫疗法的免疫学分析,评估体液和细胞激活情况
- 批准号:
449815 - 财政年份:2020
- 资助金额:
$ 19.56万 - 项目类别:
Studentship Programs
Elucidation of mechanisms for induction of regulatory T cells by IgG1 that increase in allergen immunotherapy
阐明过敏原免疫治疗中增加的 IgG1 诱导调节性 T 细胞的机制
- 批准号:
19K16385 - 财政年份:2019
- 资助金额:
$ 19.56万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The combination of allergen immunotherapy with anti-IL-4 receptor-alpha antibody (dupilumab) for induction of human allergen-specific tolerance
过敏原免疫疗法与抗 IL-4 受体-α 抗体(dupilumab)相结合,用于诱导人类过敏原特异性耐受
- 批准号:
MR/T00164X/1 - 财政年份:2019
- 资助金额:
$ 19.56万 - 项目类别:
Fellowship
Identifying the mechanism of allergen immunotherapy using single cell and bulk gene expression information.
使用单细胞和大量基因表达信息识别过敏原免疫治疗的机制。
- 批准号:
19H03696 - 财政年份:2019
- 资助金额:
$ 19.56万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Challenge for treatment of dog allergy by allergen immunotherapy using hypoallergenic vaccine
使用低过敏性疫苗进行过敏原免疫疗法治疗狗过敏的挑战
- 批准号:
17K19329 - 财政年份:2017
- 资助金额:
$ 19.56万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Development of a Dissolving Film for Allergen Immunotherapy in Children
开发用于儿童过敏原免疫治疗的溶解膜
- 批准号:
8676849 - 财政年份:2013
- 资助金额:
$ 19.56万 - 项目类别:
Development of a Dissolving Film for Allergen Immunotherapy in Children
开发用于儿童过敏原免疫治疗的溶解膜
- 批准号:
8510886 - 财政年份:2013
- 资助金额:
$ 19.56万 - 项目类别:
Proof of concept study of combined allergen immunotherapy and antibiotics for the treatment of chronic atopic dermatitis
过敏原免疫疗法和抗生素联合治疗慢性特应性皮炎的概念验证研究
- 批准号:
G0701693/1 - 财政年份:2009
- 资助金额:
$ 19.56万 - 项目类别:
Research Grant
ALLERGEN IMMUNOTHERAPY CO-ADMINISTERED WITH OMALIZUMAB, AN ANTI-IGE MAB
过敏原免疫疗法与 OMALIZUMAB(一种抗 IGE 单克隆抗体)联合使用
- 批准号:
7201329 - 财政年份:2005
- 资助金额:
$ 19.56万 - 项目类别:
Allergen Immunotherapy Co-Administered with Omalizumab
过敏原免疫疗法与奥马珠单抗联合给药
- 批准号:
7040810 - 财政年份:2004
- 资助金额:
$ 19.56万 - 项目类别: